Search Results - Vibeke Strand

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study

    Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study by Frank Buttgereit, Dorothy McCabe, Eun Bong Lee, Vibeke Strand, Abraham Simon-Campos, Astrid Genet, Brinda Tammara, Ricardo Rojo, Judith Hey-Hadavi

    Published 2019-06-01
    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

    Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to con... by Philip J Mease, Dafna D Gladman, Vibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, Daniela Graham, Cunshan Wang, Joseph C Cappelleri, Thijs Hendrikx, Ming-Ann Hsu

    Published 2019-05-01
    Get full text
    Article

    Save to List
    Saved in:
  3. 3
    Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond

    Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, ran... by Philip J Mease, Dafna D Gladman, Vibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, Joseph C Cappelleri, Thijs Hendrikx, Ming-Ann Hsu, Linda Chen, Elizabeth Kudlacz, Joseph Wu

    Published 2019-06-01
    Get full text
    Article

    Save to List
    Saved in:

Search Tools: